Back To Back FDA Approval For Takeda Within Two Days, Secures Green Signal For Rare Blood Disorder Therapy
Published
The FDA approved Takeda Pharmaceutical Co Ltd's TAK Adzynma, a recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on-demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). cTTP…
#fda #ert #cttp #adamts13 #adzynma #ttp #takeda #fruzaqla #priorityreview #tak